Squamous Cell Carcinoma of the Head and Neck – China In-Depth – Squamous Cell Carcinoma of the Head and Neck – China In-Depth (China)

Squamous cell carcinoma of the head and neck (SCCHN)—one of the most commonly diagnosed cancers in China—has a dynamic drug development pipeline, including targeted and biomarker-driven therapies. The management of locally advanced SCCHN is often complex and requires a combination of therapies / procedures including surgery, radiotherapy, and chemotherapy. For nearly a decade, the EGFR inhibitor Erbitux (Eli Lilly / Merck KGaA) was the cornerstone therapy in the treatment algorithm of SCCHN, but the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic SCCHN marked a turning point in the treatment landscape of the disease. We expect that many novel therapies will launch for the treatment of both metastatic and early-stage SCCHN during the 2021-2031 forecast period, which will lead to significant growth of this market in China. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter the growing SCCHN market.


  • How large is China’s drug-treatable SCCHN population, and how will drug-treatment rates change during the forecast period?
  • Which are the most commercially relevant drugs in China’s SCCHN therapy market, and why? What are interviewed experts’ insights into current treatments?
  • What are the market access considerations for key therapies in the SCCHN pipeline in China? What sales could these agents secure in SCCHN? What are interviewed experts’ opinions of key emerging therapies?
  • What are the key drivers and constraints in China’s SCCHN therapy market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release date

September 2022



Primary research

Country-specific qualitative and quantitative insights based on 5 thought-leader interviews and surveys of 75 medical oncologists.


Diagnosed incidence of SCCHN in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.


10-year, annualized, drug-level sales and patient share of key SCCHN therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.


Phase III/preregistered: 10+ drugs; Phase II: 20+ drugs; coverage of select Phase I products.

launch Related Market Assessment Reports